Table 2.
Clinical outcomes at one year after transplantation.
| aABOc/XM+ | aABOi/XM+ | P-value | |
|---|---|---|---|
| Number of patients, XM+ | 176 (66.9) | 87 (33.1) | |
| Overall rejection | 21 (11.7) | 25 (25.5) | <0.01 |
| ACR only | 5 (2.8) | 6 (6.1) | 0.17 |
| AMR with or without ACR | 16 (8.9) | 19 (19.4) | 0.01 |
| Number of patients, CDC+ | 14 (63.6) | 8 (36.4) | |
| Overall rejection | 0 (0.0) | 5 (62.5) | <0.01 |
| ACR only | 0 (0.0) | 0 (0.0) | — |
| AMR with or without ACR | 0 (0.0) | 5 (62.5) | <0.01 |
| Number of patients, FCXM+ | 162 (67.2) | 79 (32.8) | |
| Overall rejection | 21 (13.0) | 17 (21.5) | 0.09 |
| ACR only | 5 (3.1) | 4 (5.1) | 0.48 |
| AMR with or without ACR | 16 (9.9) | 13 (16.5) | 0.14 |
| Mortality | 0 (0.0) | 4 (4.6) | <0.01 |
| Bacterial infection | 0.14 | ||
| Urinary tract infection | 39 (21.7) | 12 (12.1) | |
| Pneumonia | 14 (7.8) | 7 (7.1) | |
| Biopsy proven BKVN | 1 (0.6) | 1 (1.1) | 0.61 |
| Surgical complications | 0.30 | ||
| Bleeding | 10 (5.6) | 2 (2.0) | |
| Urinary complications | 3 (1.7) | 3 (3.1) |
Values are presented as numbers of patients (%).
Abbreviations: ACR, acute cellular rejection; AMR, Acute antibody-mediated rejection; CDC, complement-dependent cytotoxicity; FCXM, flow-cytometric crossmatch; BKVN, BK virus nephropathy.
aCrossmatch-positive (XM+) defined as FCXM-positive and CDC XM-positive; ABOc, ABO compatible; ABOi, ABO incompatible.